/RCUS
RCUS Stock - Arcus Biosciences, Inc.
Healthcare|BiotechnologyNYSE
$21.98-0.02%
$0.01 (-0.02%) • Dec 19
86
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.90
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.90
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+36.5%upside
Target: $30.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for RCUS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$21.76 – $22.20
TARGET (TP)$30.00
STOP LOSS$20.22
RISK/REWARD1:4.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.75
52W High$26.40
52W Low$6.50
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $258.00M | $117.00M | $112.00M | $383.00M | $78.00M |
| Gross Profit | $258.00M | $117.00M | $112.00M | $383.00M | $78.00M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-330,000,000 | $-340,000,000 | $-280,000,000 | $54.00M | $-124,000,000 |
| Net Income | $-283,000,000 | $-307,000,000 | $-267,000,000 | $53.00M | $-123,000,000 |
| Net Margin | -109.7% | -262.4% | -238.4% | 13.8% | -157.7% |
| EPS | $-3.14 | $-4.15 | $-3.71 | $0.76 | $-2.13 |
Company Overview
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
33%
Hold / Neutral
2
67%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
1 Bullish2 Neutral/Bearish
Price Targets
$29
Average Target
↑ 32.8% Upside
Now
$20
Low
$29
Average
$40
High
Based on 5 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| February 26th 2025 | H.C. Wainwright | Upgrade | Buy | $24← $18 |
| October 21st 2024 | H.C. Wainwright | Initiation | Neutral | $20 |
| October 8th 2024 | Wells Fargo | Initiation | Overweight | $29 |
| November 18th 2022 | BofA Securities | Initiation | Neutral | $33 |
| October 11th 2022 | Morgan Stanley | Initiation | Overweight | $40 |
Earnings History & Surprises
RCUSBeat Rate
61%
Last 18 quarters
Avg Surprise
+32.0%
EPS vs Estimate
Beats / Misses
11/5
2 met exactly
Latest EPS
$-1.27
Q4 2025
EPS Surprise History
Q1 24
+0.9%
$-1.08vs$-1.09
Q2 24
+94.8%
$-0.05vs$-0.97
Q3 24
0.0%
$-1.02vs$-1.02
Q4 24
+6.5%
$-1.00vs$-1.07
Q1 25
+12.0%
$-1.03vs$-1.17
Q2 25
-11.8%
$-1.14vs$-1.02
Q3 25
+93.4%
$-0.08vs$-1.14
Q4 25
+4.5%
$-1.27vs$-1.33
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 24, 2026 | $-0.99 | — | — | — |
Q4 2025 | Oct 28, 2025 | $-1.33 | $-1.27 | +4.5% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $-1.14 | $-0.08 | +93.4% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $-1.02 | $-1.14 | -11.8% | ✗ MISS |
Q1 2025 | Feb 25, 2025 | $-1.17 | $-1.03 | +12.0% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $-1.07 | $-1.00 | +6.5% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-1.02 | $-1.02 | 0.0% | = MET |
Q2 2024 | May 8, 2024 | $-0.97 | $-0.05 | +94.8% | ✓ BEAT |
Q1 2024 | Feb 21, 2024 | $-1.09 | $-1.08 | +0.9% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-1.12 | $-0.94 | +16.1% | ✓ BEAT |
Q3 2023 | Aug 7, 2023 | $-1.00 | $-1.04 | -4.0% | ✗ MISS |
Q2 2023 | May 9, 2023 | $-1.06 | $-1.09 | -2.8% | ✗ MISS |
Q1 2023 | Feb 28, 2023 | $-0.99 | $-0.93 | +6.1% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $-1.05 | $-0.90 | +14.3% | ✓ BEAT |
Q3 2022 | Aug 3, 2022 | $-0.93 | $-0.93 | 0.0% | = MET |
Q2 2022 | May 9, 2022 | $0.83 | $-0.96 | -215.7% | ✗ MISS |
Q1 2022 | Feb 23, 2022 | $-0.74 | $3.71 | +601.4% | ✓ BEAT |
Q4 2021 | Nov 8, 2021 | $-1.13 | $-1.11 | +1.8% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-0.77 | $-1.09 | -41.6% | ✗ MISS |
Latest News
HC Wainwright & Co. Maintains Buy on Arcus Biosciences, Raises Price Target to $32
📈 PositiveBenzinga•Dec 12, 2025, 04:49 PM
Arcus Biosciences shares are trading lower after the company announced the discontinuation of the Phase 3 STAR-221 study.
📉 NegativeBenzinga•Dec 12, 2025, 02:00 PM
Arcus Biosciences Discontinues Phase 3 STAR-221 Study With Gilead Following IDMC Futility Recommendation
📉 NegativeBenzinga•Dec 12, 2025, 01:33 PM•Also:
B of A Securities Maintains Neutral on Arcus Biosciences, Raises Price Target to $26
➖ NeutralBenzinga•Nov 28, 2025, 05:03 PM
Arcus Biosciences shares are trading lower after the company announced the pricing of its $250 million public offering of 13.7 million shares at $18.25 per share.
📉 NegativeBenzinga•Oct 31, 2025, 01:04 PM
Reported Earlier, Arcus Biosciences Announces Pricing Of $250M Public Offering Of 13.7M Common Shares At $18.25 Per Share
➖ NeutralBenzinga•Oct 31, 2025, 07:48 AM
Arcus Biosciences shares are trading lower after the company announced a public offering.
📉 NegativeBenzinga•Oct 30, 2025, 08:38 PM
Arcus Biosciences Announces Public Offering of Common Stock; No Size Disclosed
➖ NeutralBenzinga•Oct 30, 2025, 08:27 PM
Goldman Sachs Maintains Neutral on Arcus Biosciences, Raises Price Target to $16
➖ NeutralBenzinga•Oct 30, 2025, 03:19 PM
Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $56
📈 PositiveBenzinga•Oct 29, 2025, 07:50 PM•Also:
HC Wainwright & Co. Maintains Buy on Arcus Biosciences, Raises Price Target to $28
📈 PositiveBenzinga•Oct 29, 2025, 11:03 AM
Arcus Biosciences Q3 EPS $(1.27) Beats $(1.33) Estimate, Sales $26.000M Beat $21.400M Estimate
📈 PositiveBenzinga•Oct 28, 2025, 08:39 PM
Wells Fargo Maintains Overweight on Arcus Biosciences, Raises Price Target to $29
📈 PositiveBenzinga•Oct 20, 2025, 01:36 PM
Reported Sunday, Taiho Pharmaceutical Secures Exclusive Rights To Develop And Commercialize Casdatifan In Japan And Select Asian Territories
📈 PositiveBenzinga•Oct 20, 2025, 06:59 AM
Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $54
📈 PositiveBenzinga•Oct 13, 2025, 05:47 PM•Also:
Arcus Biosciences rises on results from domvanalimab cancer study
📈 PositiveSeeking Alpha•Oct 13, 2025, 03:39 PM
Reported Earlier, Arcus Biosciences Reports 26.7-Month Median Survival From Anti-TIGIT Domvanalimab Combination In Unresectable Or Metastatic Gastroesophageal Adenocarcinoma
📈 PositiveBenzinga•Oct 13, 2025, 06:30 AM
Truist Securities Reiterates Buy on Arcus Biosciences, Raises Price Target to $39
📈 PositiveBenzinga•Oct 7, 2025, 02:15 PM
Arcus Biosciences shares are trading higher after the company announced new monotherapy data for casdatifan.
📈 PositiveBenzinga•Oct 6, 2025, 03:43 PM
Arcus Biosciences Announces New Monotherapy Data For Casdatifan, HIF-2a Inhibitor With Potential, In Late-Line Metastatic Clear Cell Renal Cell Carcinoma
📈 PositiveBenzinga•Oct 6, 2025, 12:12 PM
Frequently Asked Questions about RCUS
What is RCUS's current stock price?
Arcus Biosciences, Inc. (RCUS) is currently trading at $21.98 per share. The stock has moved -0.02% today.
What is the analyst price target for RCUS?
The average analyst price target for RCUS is $30.00, based on 1 analyst.
What sector is Arcus Biosciences, Inc. in?
Arcus Biosciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NYSE exchange.
What is RCUS's market cap?
Arcus Biosciences, Inc. has a market capitalization of $2.37 billion, making it a mid-cap company.
Does RCUS pay dividends?
No, Arcus Biosciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAGIO
Agios Pharmaceuticals, Inc.
$24.46
Mkt Cap: $1.4B
BEAM
Beam Therapeutics Inc.
$26.57
Mkt Cap: $2.7B
COGT
Cogent Biosciences, Inc.
$39.55
Mkt Cap: $5.6B
DNLI
Denali Therapeutics Inc.
$16.85
Mkt Cap: $2.5B
ETNB
89bio, Inc.
$14.84
Mkt Cap: $2.2B
GLPG
Galapagos N.V.
$32.36
Mkt Cap: $2.1B
IBRX
ImmunityBio, Inc.
$2.08
Mkt Cap: $2.0B
LQDA
Liquidia Corporation
$34.53
Mkt Cap: $3.0B
OCUL
Ocular Therapeutix, Inc.
$12.56
Mkt Cap: $2.2B
VRDN
Viridian Therapeutics, Inc.
$31.92
Mkt Cap: $2.6B
Explore stocks similar to RCUS for comparison